Numinus Wellness (NUMI) Investor Presentation summary

Strategic direction and operational highlights

• Transitioned out of Canadian clinical operations, focusing on U.S. clinics and partnerships.

• Enrolled over 1,650 learners in practitioner training from 18 countries, up from 1,400 in Q2 2024.

• Managed 15 clinical trials and provided 15,750 client appointments in U.S. clinics, a 3.2% increase year-over-year.

• Proposed acquisition of MedBright AI to relaunch as Numinus Intelligence, aiming to AI-enable mental health clinics.

• Implemented cost containment, transitioning to a leaner, more efficient organization.

Market context and growth opportunities

• Global mental health market projected to grow from $380B in 2020 to $538B by 2030.

• One in four Canadians and four in ten U.S. adults reported mental health symptoms during the pandemic.

• Psychedelic-assisted therapies, including MDMA and ketamine, show significant clinical and economic impact.

• Ketamine-assisted therapy market forecasted to reach $6.9B in the U.S. by 2030, with a 10.6% CAGR.

• Current systems are not equipped to handle rising rates of mental illness, addiction, and trauma.

Business model and service offerings

• Integrated model combines clinical therapy, psychedelic research, and practitioner training.

• Wellness clinics generate ~80,000 appointments annually, addressing a broad range of mental health needs.

• Offers traditional and novel therapies, including psychiatric services, ketamine, TMS, and MDMA/psilocybin-assisted therapies.

• Cedar Clinical Research provides contract research services for drug developers and academic institutions.

• Practitioner training programs serve over 1,650 learners globally, expanding curriculum and modalities.